Inhibikase Therapeutics, Inc.
Income Statement
| Line Item | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1 | $79.6K | $116.4K | $64.5K | $63.6K | $7.3K | $6.6K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $2.8M | $3.0M | $3.2M | $4.5M | $2.9M | $3.1M | $3.0M | $3.0M |
| SG&A Expense | $2.0M | $1.4M | $1.6M | $1.8M | $1.9M | $1.3M | $1.5M | $1.7M |
| Operating Income | $-4.8M | $-4.4M | $-4.8M | $-6.2M | $-4.7M | $-4.3M | $-4.5M | $-4.6M |
| Operating Margin | — | -440,356,600.0% | -5,993.4% | -5,328.1% | -7,307.6% | -6,819.6% | -61,899.6% | -70,817.1% |
| Interest Expense | — | — | — | — | — | — | $0 | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | $0 | $0 | $0 | — | $0 | $0 |
| Net Income | $-4.6M | $-4.2M | $-4.6M | $-5.8M | $-4.5M | $-4.3M | $-4.5M | $-4.6M |
| Net Margin | — | -417,794,000.0% | -5,775.1% | -4,963.5% | -6,940.0% | -6,731.7% | -61,645.4% | -70,817.1% |
| EPS (Basic) | $-0.05 | $-0.01 | $-0.05 | $-0.07 | $-0.06 | $-0.12 | $-0.07 | $-0.07 |
| EPS (Diluted) | $-0.05 | $-0.01 | $-0.05 | $-0.07 | $-0.06 | $-0.12 | $-0.07 | $-0.07 |
| Shares Outstanding (Basic) | 101.5M | 96.5M | 85.5M | 83.6M | 73.4M | 67.6M | 67.6M | 67.6M |
| Shares Outstanding (Diluted) | 101.5M | 96.5M | 85.5M | 83.6M | 73.4M | 67.6M | 67.6M | 67.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |